Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge

Vaccine

Volumn 25, Issue 46, 2007, Pages 7962-7971

  Rodríguez Cortés, Alhelí ^a   Ojeda, Ana ^c   López Fuertes, Laura ^b   Timón, Marcos ^b   Altet, Laura ^c   Solano Gallego, Laia ^a   Sánchez Robert, Elisenda ^c   Francino, Olga ^c   Alberola, Jordi ^a  

^a Terapeutica i Toxicologia Veterinaria   (Spain)

^b Agencia Espanola del Medicamento   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

DNA vaccine; Dog; Experimental challenge; Leishmania infantum

Indexed keywords

ANTIGEN; ANTIGEN GP63; ANTIGEN KPM II; ANTIGEN LACK; ANTIGEN TRYP; LEISHMANIA VACCINE; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOG; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; IMMUNIZATION; LEISHMANIA INFANTUM; LEISHMANIASIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMASTIGOTE; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; BRAZIL; DOG DISEASES; DOGS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MICE; PLASMIDS; VACCINATION; VACCINES, DNA; ZOONOSES;

EID: 35448983199     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.023     Document Type: Article

References (67)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27 5 (2004) 305-318
2. Desjeux P., and Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 97 (2003) 3-15 Suppl 1
3. Carvalho E.M., Teixeira R.S., and Johnson Jr. W.D. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immunol 33 2 (1981) 498-500
4. Badaro R., Jones T.C., Carvalho E.M., Sampaio D., Reed S.G., Barral A., et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 154 6 (1986) 1003-1011
5. Armijos R.X., Weigel M.M., Aviles H., Maldonado R., and Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 177 5 (1998) 1352-1357
6. Velez I.D., Gilchrist K., Arbelaez M.P., Rojas C.A., Puerta J.A., Antunes C.M., et al. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans R Soc Trop Med Hyg 99 8 (2005) 593-598
7. Satti I.N., Osman H.Y., Daifalla N.S., Younis S.A., Khalil E.A., Zijlstra E.E., et al. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 19 15-16 (2001) 2100-2106
8. Khalil E.A., El Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356 9241 (2000) 1565-1569
9. Kamil A.A., Khalil E.A., Musa A.M., Modabber F., Mukhtar M.M., Ibrahim M.E., et al. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 97 3 (2003) 365-368
10. Travi B.L., Tabares C.J., Cadena H., Ferro C., and Osorio Y. Canine visceral leishmaniasis in Colombia: relationship between clinical and parasitologic status and infectivity for sand flies. Am J Trop Med Hyg 64 3-4 (2001) 119-124
11. Gavgani A.S., Hodjati M.H., Mohite H., and Davies C.R. Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet 360 9330 (2002) 374-379
12. Dye C. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 55 2 (1996) 125-130
13. Molano I., Alonso M.G., Miron C., Redondo E., Requena J.M., Soto M., et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 92 1-2 (2003) 1-13
14. Ramiro M.J., Zarate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 19-20 (2003) 2474-2484
15. Mohebali M., Khamesipour A., Mobedi I., Zarei Z., and Hashemi-Fesharki R. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine 22 29-30 (2004) 4097-4100
16. Lemesre J.L., Holzmuller P., Cavaleyra M., Goncalves R.B., Hottin G., and Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23 22 (2005) 2825-2840
17. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23 28 (2005) 3716-3725
18. Saldarriaga O.A., Travi B.L., Park W., Perez L.E., and Melby P.C. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Vaccine 24 11 (2006) 1928-1940
19. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., de Souza E.P., Luz K.G., Palatnik M., et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine 19 9-10 (2000) 1082-1092
20. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 20 27-28 (2002) 3277-3284
21. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization*. Ann Rev Immunol 18 (2000) 927-974
22. Jiang W., Baker H.J., Swango L.J., Schorr J., Self M.J., and Smith B.F. Nucleic acid immunization protects dogs against challenge with virulent canine parvovirus. Vaccine 16 6 (1998) 601-607
23. Osorio J.E., Tomlinson C.C., Frank R.S., Haanes E.J., Rushlow K., Haynes J.R., et al. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine 17 9-10 (1999) 1109-1116
24. Cherpillod P., Tipold A., Griot-Wenk M., Cardozo C., Schmid I., Fatzer R., et al. DNA vaccine encoding nucleocapsid and surface proteins of wild type canine distemper virus protects its natural host against distemper. Vaccine 18 26 (2000) 2927-2936
25. Chang K.P., Chaudhuri G., and Fong D. Molecular determinants of leishmania virulence. Annu Rev Microbiol 44 (1990) 499-529
26. Xu D., and Liew F.Y. Genetic vaccination against leishmaniasis. Vaccine 12 16 (1994) 1534-1536
27. Dumonteil E., Andrade-Narvarez F., Escobedo-Ortegon J., Ramirez-Sierra M.J., Valencia-Pacheco G., Flores-Serrano A., et al. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana. Dev Biol (Basel) 104 (2000) 135-141
28. Rhalem A., Sahibi H., Guessous-Idrissi N., Lasri S., Natami A., Riyad M., et al. Immune response against Leishmania antigens in dogs naturally and experimentally infected with Leishmania infantum. Vet Parasitol 81 (1999) 173-184
29. Lasri S., Sahibi H., Natami A., and Rhalem A. Western blot analysis of Leishmania infantum antigens using sera from pentamidine-treated dogs. Vet Immunol Immunopathol 91 1 (2003) 13-18
30. Julia V., and Glaichenhaus N. CD4(+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10. D2 mice. Infect Immun 67 7 (1999) 3641-3644
31. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186 7 (1997) 1137-1147
32. Tolson D.L., Jardim A., Schnur L.F., Stebeck C., Tuckey C., Beecroft R.P., et al. The kinetoplastid membrane protein 11 of Leishmania donovani and African trypanosomes is a potent stimulator of T-lymphocyte proliferation. Infect Immun 62 11 (1994) 4893-4899
33. Kurtzhals J.A., Hey A.S., Jardim A., Kemp M., Schaefer K.U., Odera E.O., et al. Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients. Clin Exp Immunol 96 3 (1994) 416-421
34. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174 11 (2005) 7160-7171
35. Skeiky Y.A., Coler R.N., Brannon M., Stromberg E., Greeson K., Crane R.T., et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20 27-28 (2002) 3292-3303
36. Fujiwara R.T., Vale A.M., Franca da Silva J.C., da Costa R.T., Quetz Jda S., Martins Filho O.A., et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 36 5-6 (2005) 827-838
37. Gradoni L., Foglia Manzillo V., Pagano A., Piantedosi D., De Luna R., Gramiccia M., et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23 45 (2005) 5245-5251
38. Coler R.N., and Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol 21 5 (2005) 244-249
39. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14 2 (2001) 229-243
40. Polvi A., Garden O.A., Elwood C.M., Sorensen S.H., Batt R.M., Maki M., et al. Canine major histocompatibility complex genes DQA and DQB in Irish setter dogs. Tissue Antigens 49 3 Pt 1 (1997) 236-243
41. Lopez-Fuertes L., Perez-Jimenez E., Vila-Coro A.J., Sack F., Moreno S., Konig S.A., et al. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 21 3-4 (2002) 247-257
42. Fragaki K., Suffia I., Ferrua B., Rousseau D., Le Fichoux Y., and Kubar J. Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine 19 13-14 (2001) 1701-1709
43. Rodriguez-Cortes A., Ojeda A., Lopez-Fuertes L., Timon M., Altet L., Solano-Gallego L., et al. A long term experimental study of canine visceral leishmaniasis. Int J Parasitol 37 6 (2007) 683-693
44. Rodriguez A., Solano-Gallego L., Ojeda A., Quintana J., Riera C., Gallego M., et al. Dynamics of Leishmania-specific immunoglobulin isotypes in dogs with clinical leishmaniasis before and after treatment. J Vet Intern Med 20 3 (2006) 495-498
45. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21 (1968) 77-89
46. Solano-Gallego L., Llull J., Ramos G., Riera C., Arboix M., Alberola J., et al. The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection. Vet Parasitol 90 1-2 (2000) 37-45
47. Francino O., Altet L., Sanchez-Robert E., Rodriguez A., Solano-Gallego L., Alberola J., et al. Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis. Vet Parasitol 137 3-4 (2006) 214-221
48. Bretagne S., Durand R., Olivi M., Garin J.F., Sulahian A., Rivollet D., et al. Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected mice. Clin Diagn Lab Immunol 8 4 (2001) 828-831
49. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 4 (2001) 402-408
50. Johnson P.A., Conway M.A., Daly J., Nicolson C., Robertson J., and Mills K.H. Plasmid DNA encoding influenza virus haemagglutinin induces Th1 cells and protection against respiratory infection despite its limited ability to generate antibody responses. J Gen Virol 81 Pt 7 (2000) 1737-1745
51. d'Oliveira C., Feenstra A., Vos H., Osterhaus A.D., Shiels B.R., Cornelissen A.W., et al. Induction of protective immunity to Theileria annulata using two major merozoite surface antigens presented by different delivery systems. Vaccine 15 16 (1997) 1796-1804
52. Babiuk L.A., van Drunen Littel-van den H., and Babiuk S.L. Immunization of animals: from DNA to the dinner plate. Vet Immunol Immunopathol 72 1-2 (1999) 189-202
53. Altet L., Francino O., Solano-Gallego L., Renier C., and Sanchez A. Mapping and sequencing of the canine NRAMP1 gene and identification of mutations in leishmaniasis-susceptible dogs. Infect Immun 70 6 (2002) 2763-2771
54. Poot J., Rogers M.E., Bates P.A., and Vermeulen A. Detailed analysis of an experimental challenge model for Leishmania infantum (JPC strain) in dogs. Vet Parasitol 130 1-2 (2005) 41-53
55. Satti I., el Hassan A., Khalil el T.A., and Akuffo H. The effect of repeated leishmanin skin testing on the immune responses to Leishmania antigen in healthy volunteers. Trans R Soc Trop Med Hyg 96 5 (2002) 565-567
56. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 2 (2005) 633-639
57. Liu M.A., and Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 55 (2005) 25-40
58. Peachman K.K., Rao M., and Alving C.R. Immunization with DNA through the skin. Methods 31 3 (2003) 232-242
59. Drabick J.J., Glasspool-Malone J., King A., and Malone R.W. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther 3 2 (2001) 249-255
60. Fuller D.H., Corb M.M., Barnett S., Steimer K., and Haynes J.R. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine 15 8 (1997) 924-926
61. Ulmer J.B., Wahren B., and Liu M.A. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 12 5 (2006) 216-222
62. Quinnell R.J., Courtenay O., Shaw M.A., Day M.J., Garcez L.M., Dye C., et al. Tissue cytokine responses in canine visceral leishmaniasis. J Infect Dis 183 9 (2001) 1421-1424
63. Moreno J., and Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol 18 9 (2002) 399-405
64. Gurunathan S., Prussin C., Sacks D.L., and Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 4 12 (1998) 1409-1415
65. Tewary P., Saxena S., and Madhubala R. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis. Vaccine 24 13 (2006) 2409-2416
66. Poot J., Spreeuwenberg K., Sanderson S.J., Schijns V.E., Mottram J.C., Coombs G.H., et al. Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum. Vaccine 24 14 (2006) 2460-2468
67. Ramshaw I.A., and Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 21 4 (2000) 163-165